Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-08-27 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through a public stock issuance by Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes specifics on the amount raised, usage, balance, investment projects, and compliance with regulatory requirements. The document references approvals from the China Securities Regulatory Commission and the Beijing Stock Exchange, and includes financial figures and audit confirmations related to the fundraising. This type of document is a specialized report on the use of raised capital, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim report, nor an announcement of a report publication. The length and detail confirm it is a substantive report rather than a brief announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '半年度报告摘要' which translates to 'Half-Year Report Summary' and contains detailed financial data for a half-year period, including assets, net profit, earnings per share, and other financial metrics. It also includes company business descriptions, shareholder information, and management assurances about the report's accuracy. The document explicitly states it is an unaudited half-year report summary and references the full half-year report on the stock exchange website. The length is about 4869 characters, which is sufficient to contain substantive financial data and analysis. Therefore, this document is a comprehensive interim/quarterly financial report for a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive report covering a six-month period (2024-01-01 to 2024-06-30) for Zhejiang Chemsyn Pharm Co., Ltd. It includes detailed financial data such as income, profit, cash flow, asset and liability structure, business overview, risk factors, and operational analysis. The document explicitly states it is a "半年度报告" (half-year report) and contains extensive financial statements and management discussion. It is not a brief announcement or a certification letter but a full interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It details the authorization, amounts, types of financial products purchased, risk control measures, and related disclosures. The document is relatively short (3334 characters) and focuses on a specific financing activity related to the use of idle raised funds for cash management and investment in structured deposits. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The content fits best with an update on capital/financing activities, specifically the use of raised funds for financial product investments. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-08-05 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle proprietary funds to purchase financial products. It details the authorization, amounts, counterparties, risk controls, and investment specifics. The document is relatively short (3795 characters) and focuses on a specific financing activity related to cash management and investment of idle funds. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about capital management activities, specifically the use of idle funds for purchasing financial products. Therefore, it fits best under Capital/Financing Update (CAP).
2024-07-14 Chinese
关于使用部分闲置募集资金及闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds and idle own funds to purchase financial products. It details the authorization, amounts, types of financial products, risk control measures, and investment returns. The document is a disclosure about the company's cash management and investment activities, specifically the use of idle funds for purchasing structured deposits and other financial products. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or a voting result announcement. The document is a progress announcement about capital/financing activities related to the use of funds and investments. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4513 characters, which is sufficient for a detailed announcement but not a full financial report.
2024-07-02 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.